Cao Lanqing, Sun Ping-Li, Yao Min, Jia Meng, Gao Hongwen
Department of Pathology, The Second Hospital of Jilin University, Changchun, Jilin 130041, China.
Hum Pathol. 2017 Oct;68:166-174. doi: 10.1016/j.humpath.2017.08.032. Epub 2017 Sep 9.
The transcriptional co-activator YES-associated protein (YAP) has been reported to act as both an oncogene and tumor suppressor in breast cancers. In this study, we evaluated YAP expression immunohistochemically in 324 breast cancer tissues and correlated the expression with clinicopathological findings and patient survival data. Additionally, we reviewed the literature to clarify the role of YAP in breast cancer. We detected YAP, estrogen receptor, progesterone receptor (PR), and human epidermal growth receptor-2 (HER2) expression and a Ki67 labeling index >20% in 53.4%, 49.0%, 45.0%, 28.3%, and 57.4% of invasive ductal carcinoma tissues, respectively. YAP is mainly localized within the tumor cell nuclei, and its expression was associated with the PR status and luminal A subtype. YAP expression also inversely correlated with the HER2 and Ki67 levels and lymph node metastasis. Kaplan-Meier curves revealed associations of YAP expression with favorable disease-free survival (DFS) and overall survival in patients with luminal A breast cancer and with favorable DFS association among patients with invasive ductal carcinoma, luminal B (HER2-), and luminal B (HER2+) breast cancers. A multivariate Cox analysis revealed that YAP expression and PR status were independent favorable predictors of DFS and overall survival, respectively, among patients with breast cancer, whereas tumor-node-metastasis stage and an old age were independent predictors of a poor DFS. Our results, together with the literature review findings, suggest that YAP could be a prognostic marker in patients with breast cancer.
据报道，转录共激活因子Yes相关蛋白（YAP）在乳腺癌中既作为癌基因又作为肿瘤抑制因子发挥作用。在本研究中，我们通过免疫组织化学方法评估了324例乳腺癌组织中YAP的表达情况，并将其表达与临床病理结果及患者生存数据进行关联分析。此外，我们查阅了文献以阐明YAP在乳腺癌中的作用。我们在53.4%、49.0%、45.0%、28.3%和57.4%的浸润性导管癌组织中分别检测到YAP、雌激素受体、孕激素受体（PR）、人表皮生长因子受体2（HER2）的表达以及Ki67标记指数>20%。YAP主要定位于肿瘤细胞核内，其表达与PR状态和管腔A型亚型相关。YAP表达还与HER2和Ki67水平及淋巴结转移呈负相关。Kaplan-Meier曲线显示，YAP表达与管腔A型乳腺癌患者良好的无病生存期（DFS）和总生存期相关，且与浸润性导管癌、管腔B（HER2阴性）和管腔B（HER2阳性）型乳腺癌患者的良好DFS相关。多因素Cox分析显示，在乳腺癌患者中，YAP表达和PR状态分别是DFS和总生存期的独立有利预测因素，而肿瘤-淋巴结-转移分期和高龄是DFS不良的独立预测因素。我们的结果与文献综述结果共同表明，YAP可能是乳腺癌患者的一个预后标志物。
